Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Keymed Biosciences (2162 HK)
Watchlist
65
Analysis
Health Care
•
Hong Kong
Keymed Biosciences Inc. operates a biotechnology company. The Company focus on the in-house discovery and development of innovative biological therapies. Keymed Biosciences provides services in China.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Thematic (Sector/Industry)
•
26 Sep 2022 08:35
China Healthcare Weekly (Sep.25) - CXO Trading Strategy, Plunge in Medical Beauty, Belief in Biotech
If investor still want to trade CXO,here are two suggestions; The plunge in medical beauty sector last week was due to industry-wide...
Xinyao (Criss) Wang
Follow
304 Views
Share
bullish
•
Lepu Biopharma
•
27 Jun 2022 00:39
Lepu Biopharma (2157 HK): Lead Candidate Marching Toward Commercialization; Pipeline Is Progressing
Lepu is preparing for commercialization of pucotenlimab for two indications in China, after approval. The indications targeted by Lepu’s core drug...
Tina Banerjee
Follow
560 Views
Share
bullish
•
Keymed Biosciences
•
20 Jun 2022 08:50
Keymed Biosciences (2162.HK) - The Potential for Doubling Valuation and the Corresponding Risks
As long as Keymed can successfully develop either CM310 or CM326, even temporarily only commercializing in China market, Keymed has the potential...
Xinyao (Criss) Wang
Follow
304 Views
Share
bearish
•
Shanghai Junshi Biosciences
•
14 Jun 2022 08:30
Shanghai Junshi Bioscience Placement- Junshi Is Having a Hard Time, with Lower than Expected Returns
Junshi's Achilles heel is lack of cash and is in difficult time. PD-1/COVID-19 products can't relieve cashflow pressure.The uncertain outlook/macro...
Xinyao (Criss) Wang
Follow
294 Views
Share
bullish
•
Remegen
•
07 Jun 2022 09:00
Remegen (9995HK) Vs Keymed Biosciences (2162HK)-Deep Dive the Logic & Internationalization Prospects
Commercialization prospects of China autoimmune disease market are lower than expected. We analyzed RemeGen/Keymed's peak sales,...
Xinyao (Criss) Wang
Follow
329 Views
Share
First
Previous
5
6
7
8
9
10
11
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.33.9
x